Why Arm Holdings Stock Sank by Over 15% This Week
The company's second-quarter results displeased many investors.
They also inspired some analyst price target cuts.
10 stocks we like better than Arm Holdings ›
Arm Holdings (NASDAQ: ARM) felt something like an unwanted limb over the past few days, largely because of an earnings report that struck the wrong chord with more than a few investors. Several analyst price target cuts only highlighted this disappointment. Ultimately, according to data compiled by S&P Global Market Intelligence, the specialty tech company's shares plummeted by over 15% this week.
Top-line growth, bottom-line slide
U.K.-based Arm published its results for the first quarter of its fiscal 2026 on Wednesday. The report showed that the company managed to increase its total revenue by 12% year over year to slightly more than $1.05 billion. That was largely due to a 25% increase in royalty revenue, which landed at $585 million, and despite a 1% slump in licensing revenue to $468 million.
Non- GAAP (adjusted) net income traveled in the opposite direction. It fell to $374 million, or $0.35 per share, compared with the year-ago profit of $419 million. With those numbers, Arm met the consensus analyst estimate for profitability, although it missed slightly on revenue -- pundits following the stock were expecting it to earn $1.06 billion.
More of a concern for investors was management's guidance for the company's current (second) quarter. Its forecast is for $1.01 billion to $1.11 billion in revenue, which, if achieved, would be down or, at best, essentially flat over the first quarter. Meanwhile, adjusted earnings were forecast at $0.29 to $0.37.
Bearish analyst moves
Although analyst reactions to the quarter were mixed, enough pundits trimmed their price targets to affect sentiment on the stock. UBS 's Timothy Arcuri, for one, shaved his fair value assessment to $175 per Arm share from his preceding $185. He did, however, maintain his buy recommendation. Lee Simpson of Morgan Stanley acted similarly, reducing the price target to $180 per share from $194 while keeping an overweight (buy, in other words) rating intact.
Should you invest $1,000 in Arm Holdings right now?
Before you buy stock in Arm Holdings, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Arm Holdings wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!*
Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 29, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
27 minutes ago
- Globe and Mail
KBRA Affirms Assured Guaranty's AA+ Insurance Financial Strength Ratings with Stable Outlook
Assured Guaranty Ltd. (NYSE: AGO) (together with its subsidiaries, Assured Guaranty) announced that Kroll Bond Rating Agency, LLC (KBRA) has affirmed the AA+ insurance financial strength ratings of Assured Guaranty Inc. (AG) and its insurance subsidiaries, Assured Guaranty UK Limited (AGUK) and Assured Guaranty (Europe) SA (AGE). All the ratings have Stable Outlooks. In its August surveillance report affirming the AA+ ratings of AG, AGUK and AGE, KBRA cited: 'AG's rating reflects its substantial claims-paying resources, strong risk management platform, and leadership position in the financial guaranty market.' 'AG maintains a robust capital position, with claims-paying resources that provide meaningful protection against KBRA's modeled stress-case loss scenarios.' 'The merger of Assured Guaranty Municipal Corp. (AGM) into AG in 2024 has simplified the organizational structure and improved capital and regulatory efficiency.' 'AG's conservative investment approach, experienced management team, and diversified business platform support its ability to manage through credit cycles.' 'Municipal market insured penetration has increased and is currently at its highest levels since 2009.' 'AGUK and AGE are supported by a suite of intra-group financial arrangements with AG, including co-insurance, quota share and excess of loss reinsurance, as well as a net worth maintenance agreement. These agreements are key factors in KBRA's financial strength ratings for both entities.' KBRA also stated that, 'In 2024, AG originated approximately $32 billion in gross par, its highest annual total in over a decade. Growth was led by strong U.S. municipal production and selective participation in international infrastructure and structured finance.' 'We are pleased that KBRA has continued to affirm the AA+ (Stable Outlook) rating for AG and its insurance subsidiaries, AGUK and AGE, citing our robust capital position and strong claims-paying resources along with the company's high-quality insured portfolio and experienced management team, which supports our ability to navigate through credit cycles,' said Dominic Frederico, President and CEO of Assured Guaranty. 'We believe that Assured Guaranty's success reflects the market's appreciation of our consistent record of profitability, diversified business strategy, disciplined underwriting and pricing and the capital-generating power of our proven business model.' Cautionary Statement Regarding Forward-Looking Statements Any forward-looking statements made in this press release, including those regarding growth opportunities for Assured Guaranty, demand for its product, and the strength of Assured Guaranty's capital position, reflect Assured Guaranty's current views with respect to future events and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. These risks and uncertainties include, but are not limited to, difficulties executing Assured Guaranty's business strategy; those risks and uncertainties resulting from changes in rating agency models or opinions; the adequacy of Assured Guaranty's capital and its ability to manage such capital; Assured Guaranty's positioning for future global underwriting growth, unearned premiums, earnings power and financial strength; difficulties producing and sustaining new business; the benefits of Assured Guaranty's value proposition; adverse credit developments in Assured Guaranty's insured portfolio and the impact of those developments on rating agency models and opinions; insured losses in excess of those expected by Assured Guaranty or the failure of Assured Guaranty to realize loss recoveries that are assumed in its expected loss estimates for insurance exposures; other risks and uncertainties that have not been identified at this time, management's response to these factors, and other risk factors identified in Assured Guaranty's filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which are made as of August 5, 2025. Assured Guaranty undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. About Assured Guaranty Ltd. Assured Guaranty Ltd. is a publicly traded (NYSE: AGO), Bermuda-based holding company. Through its subsidiaries, Assured Guaranty provides credit enhancement products to the U.S. and non-U.S. public finance, infrastructure and structured finance markets. Assured Guaranty also participates in the asset management business through its ownership interest in Sound Point Capital Management, LP and certain of its investment management affiliates. More information on Assured Guaranty Ltd. and its subsidiaries can be found at
Globe and Mail
an hour ago
- Globe and Mail
These 3 CEOs Just Bought the Dip
Investors closely monitor insider buys, as they can give hints surrounding the long-term picture. But it's critical to note that insiders have a longer holding period than most, and many strict rules apply to their transactions. Recently, CEOs of several companies – MSCI (MSCI), Charter Communications (CHTR), and Healthpeak Properties (DOC) – have made splashes, acquiring shares. Let's take a closer look at the transactions for those interested in trading like the insiders. MSCI CEO Buys Millions Worth MSCI provides investment decision support tools, including indexes; portfolio construction and risk management products and services; Environmental, Social and Governance (ESG) research and ratings; and real estate research, reporting and benchmarking offerings. The stock is a Zacks Rank #2 (Buy) thanks to positive EPS revisions, with analysts taking expectations higher across the board over recent months. Henry Fernandez, CEO, recently has purchased roughly 12.5k MSCI shares, with the total transaction totaling roughly $6.7 million. As shown below, the purchase aligned with a dip in MSCI shares, reflective of confidence in the positive EPS and broader long-term outlook. CHTR CEO Dives In Charter Communications is the second-largest cable operator in the United States and a leading broadband communications company providing video, internet, and voice services. CEO Christopher Winfrey recently purchased roughly 3.6k CHTR shares at a total transaction value of just over $1 million. As shown below, the purchase coincided with a plunge in CHTR shares, with the CEO scooping up shares at a discounted level. X Still, analysts have lowered their EPS outlooks across the board, likely reflective of further short-term pain ahead. Positive EPS revisions would be key for a positive turnaround in sentiment, with the CEO's long holding horizon an obvious advantage here. Healthpeak CEO Buys Healthpeak Properties is a REIT in the United States that acquires, develops, manages, sells, and leases a diverse portfolio of healthcare real estate-related properties. Insiders have regularly bought on share weakness in 2025, as we can see in the green arrows in the chart below. X CEO Scott Brinker recently swooped in and purchased roughly 6k DOC shares at a total transaction value of roughly $100k. He now owns more than 210k shares overall. The stock's weak performance has been partly driven by negative earnings estimate revisions, currently a Zacks Rank #4 (Sell). The purchases here are relatively unsurprising, given the CEO's long-term horizon and the discount that shares are currently displaying. However, near-term performance can be expected to remain soft given the cloudy EPS outlook. Bottom Line Many investors closely monitor insider buys, looking to receive insights into the longer-term picture. The transactions shouldn't be relied on for near-term performance, as insiders' holding periods are longer than most, and many strict rules apply. Rather, investors can see insider buys as an overall net positive concerning the longer-term outlook. All large-cap stocks above – Healthpeak Properties DOC, MSCI MSCI, and Charter Communications CHTR – have seen recent insider activity. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> MSCI Inc (MSCI): Free Stock Analysis Report
Globe and Mail
an hour ago
- Globe and Mail
BWXT (BWXT) Revenue Jumps 12%
Key Points Revenue (GAAP) reached $764.0 million for Q2 2025, exceeding the $711.1 million GAAP estimate and up 12% compared to Q2 2024. Non-GAAP EPS was $1.02 for Q2 2025, above the $0.79 non-GAAP estimate and a 24% increase year over year. Record order backlog grew 70.2% year-over-year in Q2 2025, with management raising full-year 2025 revenue and non-GAAP earnings guidance. These 10 stocks could mint the next wave of millionaires › BWX Technologies (NYSE:BWXT), a key supplier of nuclear components to the U.S. government and commercial markets, reported its Q2 2025 results on August 4, 2025. Revenue (GAAP) was $764.0 million, handily beating analysts' GAAP estimates of $711.1 million. Non-GAAP earnings per share reached $1.02, outperforming the $0.79 non-GAAP consensus. The company's backlog grew sharply, reaching $6.0 billion, supporting a raised revenue and non-GAAP earnings forecast for 2025. Overall, the quarter delivered strong growth and operational results, though ongoing challenges in commercial profit margins were noted. Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change EPS (Non-GAAP) $1.02 $0.79 $0.82 24% Revenue (GAAP) $764.0 million $711.06 million $681.5 million 12% Adjusted EBITDA $145.9 million $126.2 million 16% Operating Income (GAAP) $102.4 million $98.8 million 4% Free Cash Flow $126.3 million $35.5 million 256.1% Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Business Overview and Key Success Factors BWX Technologies operates in two main segments: Government Operations and Commercial Operations. The Government segment designs and manufactures nuclear components for the U.S. Navy and Department of Energy, including propulsion systems for submarines and aircraft carriers. The Commercial segment supplies nuclear power components, life-extension services for nuclear plants, and medical isotopes used in healthcare imaging and treatments. The company's growth depends on demand from the U.S. government, which usually provides steady, multi-year contracts. Its commercial business responds to global demand for nuclear power and medical isotopes. Strategic investments and acquisitions, such as the recent purchase of Kinectrics, help expand BWXT's technical capabilities and address new markets. Notable Developments in the Quarter The quarter saw a sharp rise in revenue, driven by outperformance in both core segments. Government Operations produced $589.0 million in GAAP revenue, up 9% from the prior-year quarter, with operating income (GAAP) rising 18%. A highlight was a record backlog of $4.44 billion in this segment, up over 54% compared to Q2 2024. Key contract wins included new pricing agreements for naval reactors—a core business anchored in federal defense spending priorities. Management noted, "exceptionally strong second quarter 2025 financial results driven by solid operational performance and pacing of work, particularly in Government Operations," Commercial Operations delivered revenue of $176.1 million, representing 24% growth compared to Q2 2024, but the segment's operating income (GAAP) dropped 59%. The decline resulted from unfavorable project mix and increased costs, especially raw material inflation in products like nuclear fuel tubing. Import cost pressures, most notably zirconium, affected profitability. Management expects relief in the second half of 2025 as cost pass-through mechanisms kick in under existing contracts. The commercial backlog more than doubled from $669 million in Q2 2024 to $1.58 billion, reflecting demand in nuclear and medical markets. The company closed its acquisition of Kinectrics in May 2025. This move aims to grow BWXT's capacity in nuclear lifecycle services and radiopharmaceuticals, contributing to the Commercial segment. Both recent acquisitions—Kinectrics and Aerojet Ordnance Tennessee—added to revenue during the quarter and contributed to the consolidated order backlog reaching a record $6.0 billion at quarter end. Alongside this, the company kept pace with expansion plans, including scaled-up manufacturing at its Cambridge facility in Canada. On a consolidated basis, adjusted EBITDA rose 16% to $145.9 million. Operating income (GAAP) was up 4%, reflecting gains in Government Operations mostly offset by lower profits in Commercial. Free cash flow (non-GAAP) improved significantly, rising to $126.3 million from $35.5 million in Q2 2024, aided by improved working capital discipline and contract award timing. BWXT paid $23.1 million in dividends during the quarter, reflecting a steady $0.25 per share payout. Financial Outlook and What to Watch Next Management raised its financial outlook for 2025, increasing guidance for adjusted EBITDA, non-GAAP EPS, and free cash flow, now projecting revenue near $3.1 billion (previously ~$3.0 billion) and non-GAAP EPS of $3.65–$3.75 (up from $3.40–$3.55). Adjusted EBITDA is now expected between $565 million and $575 million, while free cash flow guidance climbed to $275–$285 million. This enhanced forecast is backed by the strong backlog and robust first-half order trends. The company's CEO stated, ""Based on our strong year-to-date results, robust bookings, and favorable market outlook, we are increasing our 2025 financial guidance metrics,"" Investors will want to watch margin recovery in Commercial Operations as cost pass-through protections are implemented, and how well BWXT integrates newly acquired businesses. The company's exposure to U.S. government budgets remains a central factor—any major changes in defense spending or procurement could affect financial results in future periods. Raw material costs and progress in expanding medical radioisotopes capability are also key variables. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,019%* — a market-crushing outperformance compared to 178% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025
